U.S., April 17 -- ClinicalTrials.gov registry received information related to the study (NCT06929507) titled 'Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients' on April 07.
Brief Summary: This study aims to investigate the impact of intravitreal injection of anti-vascular endothelial growth factor (anti VEGF) Faricimab on renal function of diabetic patients. Faricimab is a new anti-VEGF drug which inhibits both VEGF-A and Ang-2 and it is used for the treatment of diabetic macular edema and neovascular age related macular degeneration. It is known that previous anti-VEGF agents has systematic absorption and may cause deterioration in renal function of the patients. However, the effect of Faricimab on kidney function h...